□一苇全球减肥药行业正通过“以价换量”策略打开需求空间。高盛报告显示,礼来与美国政府达成的定价协议将从2026年起降低GLP-1药物价格,并纳入联邦医保(Medicare)覆盖,同时直接面向消费者(DTC)的销售渠道和远程医疗平台降低用药门槛,共同推动市场消费化趋势加速。这一背景下,机构预测2030年全球抗肥胖药物市场规模将达1020亿美元,较此前预期显著上调。中国市场则受益于政策红利,国家药监局...
Source Link□一苇全球减肥药行业正通过“以价换量”策略打开需求空间。高盛报告显示,礼来与美国政府达成的定价协议将从2026年起降低GLP-1药物价格,并纳入联邦医保(Medicare)覆盖,同时直接面向消费者(DTC)的销售渠道和远程医疗平台降低用药门槛,共同推动市场消费化趋势加速。这一背景下,机构预测2030年全球抗肥胖药物市场规模将达1020亿美元,较此前预期显著上调。中国市场则受益于政策红利,国家药监局...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.